Abstract:Purpose: Adults with inflammatory bowel disease (IBD) are at an increased risk for developing herpes zoster compared with the general population. In 2008, the Center for Disease Control Advisory Committee on Immunization Practices recommended that patients receiving low dose immunomodulators (methotrexate [≤ 0.4 mg/kg/week], azathioprine [≤ 3.0 mg/kg/day], or 6-mercaptopurine [≤ 1.5 mg/kg/day]) are not considered sufficiently immunosuppressed to create vaccine safety concerns and are not contraindications for administration of herpes zoster vaccine (HZV). Despite these recommendations, few IBD patients are receiving the HZV. Given the morbidity and mortality of zoster, appropriately vaccinating against this virus has important clinical implications. The aims of our study were to (1) demonstrate the safety of administering the HZV in IBD patients and (2) to determine if IBD patients are able to mount an immune response to a single vaccination. Methods: An ongoing prospective open-label study at Boston Medical Center has enrolled 17 (out of the intended 80) patients with IBD over the age of 50 (mean age 63 yrs) who were eligible to receive the HZV. Patient details, medications and disease activity were recorded. Pre- and post-vaccination antibody and cytokine responses (as a measure of immune memory to vaccine antigens) were measured. Subjects were followed for all adverse events from day 1 to day 42 post-vaccination. Results: Six patients had ulcerative colitis and 11 had Crohn's disease. Of the 17 patients enrolled, 8 (47%) were on low dose immunosuppression at the time of the HZV. This included two patients on MTX and 6 patients on a thiopurine. None of the patients developed a varicella-like rash and none noted an increase in IBD activity. Four patients reported a transient headache at the one-week follow up call but overall, the vaccine was well tolerated. Patients on immunosuppressive therapy did not increase HZV-specific antibody levels compared to the response noted in the immunocompetent group (p=0.13 vs P=0.01); however, baseline levels were not different between the two groups. Furthermore, although immunosuppressed patients were able to mount a statistically significant cytokine response following vaccination it was reduced compared to the immunocompetent group (p=0.04). Conclusion: Immunocompetent patients with IBD vaccinated with HZV were able to increase their antibody response to the vaccine antigens. In contrast, immunosuppressed patients had much lower responses. Additional studies are needed to determine the clinical significance of this blunted response and whether the immunological response is protective or requires an altered vaccination protocol.

Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseases

Towards a personalized preventive strategy of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an ad hoc Italian expert panel

Herpes zoster (HZ) vaccine coverage and confidence in Italy: a Nationwide cross-sectional study, the OBVIOUS project

Herpes Zoster Infection and Statins: Which Implications in Clinical Practice?

Anti-Herpes Zoster Vaccination of Fragile Patients in Hospital Setting: A Nudge Intervention in Italy

European consensus‐based (S2k) Guideline on the Management of Herpes Zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis

Association of asthma and herpes zoster, the role of vaccination: A literature review

Healthy ageing: Herpes zoster infection and the role of zoster vaccination

Logistic and organizational barriers to herpes zoster vaccination in europe: A systematic review

The Burden of Herpes Zoster on Hospital Admissions: A Retrospective Analysis in the Years of 2015–2021 from the Abruzzo Region, Italy

Knowledge, Attitudes and Practices Survey of Recombinant Zoster Vaccine among Cardiologists and Cardiac Nurses in Italy

Herpes Zoster bei entzündlich-rheumatischen Erkrankungen

The herpes zoster subunit vaccine

Herpes zoster: A Review of Clinical Manifestations and Management

Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021–23

Recommendations and guidance for herpes zoster vaccination for adults in Taiwan

Herpes Zoster and Post-Herpetic Neuralgia—Diagnosis, Treatment, and Vaccination Strategies

Herpes Zoster Vaccine Uptake and Active Campaign Impact, a Multicenter Retrospective Study in Italy

Immune Response and Safety of Herpes Zoster Vaccine in Ibd Patients on Methotrexate or Thiopurines

Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU/EEA, Switzerland, and the UK

Efficacy, Effectiveness, and Safety of Herpes Zoster Vaccine in Immunocompromised Patients